Posted by Michael Wonder on 23 Mar 2021
FDA approves pembrolizumab for oesophageal or GEJ carcinoma
22 March 2021 - Today the FDA approved pembrolizumab (Keytruda, Merck Sharp & Dohme) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced oesophageal or gastroesophageal (tumours with epicenter 1 to 5 centimeters above the gastro-esophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation.
Efficacy was evaluated in KEYNOTE-590, a multicenter, randomized, placebo-controlled trial that enrolled 749 patients with metastatic or locally advanced oesophageal or gastro-esophageal junction carcinoma who were not candidates for surgical resection or definitive chemoradiation.
